Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region
Andrew I. Flyak(Vanderbilt University), James E. Crowe(Vanderbilt University Medical Center), Alexander Bukreyev(Galveston College), Christopher Bryan, Natalia A. Kuzmina(Galveston College), Kai Huang(Galveston College), Philipp A. Ilinykh(Houston Methodist), Pavlo Gilchuk(AstraZeneca (Japan)), Nurgun Kose(Vanderbilt University Medical Center), Christopher P. Gulka(Vanderbilt University Medical Center), Hannah L. Turner(Scripps Research Institute), Hannah A. D. King(Henry M. Jackson Foundation), Edgar Davidson(Integral Molecular (United States)), David W. Wright(Vanderbilt University), Gopal Sapparapu(Vanderbilt University Medical Center), Benjamin J. Doranz(Integral Molecular (United States)), Charles D. Murin(Scripps Research Institute), Andrew B. Ward(Scripps Research Institute), Erica Ollmann Saphire(La Jolla Institute for Immunology), Xiaoli Shen(Nanchang University), Palaniappan Ramanathan(The University of Texas Medical Branch at Galveston), Rebecca Lampley(National Institutes of Health), Thomas G. Ksiazek(The University of Texas Medical Branch at Galveston), Marnie L. Fusco(Scripps Research Institute)
Cited by 90
Related Papers
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
|Science|2003|2.6k
Nipah Virus: A Recently Emergent Deadly Paramyxovirus
|Science|2000|1.4k
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
|Proceedings of the National Academy of Sciences|2017|1.2k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k